Background The rates of death are high among patients with coinfection with tuberculosis
and the human immunodeficiency virus (HIV). The optimal timing for the initiation of …

SARS-CoV-2 variant of concern (VoC), omicron, 2 was reported. Omicron emerged in a
COVID-19-weary world in which anger and frustration with the pandemic are rife amid …

… Salim S. Abdool Karim is a member of the COVID advisory panel for emerging markets at …
If material is not included in the article’s Creative Commons license and your intended use …

… Although there is no evidence that antiviral agents and antiinflammatory treatments are
any less effective with the emerging variants than with the preexisting variants, treatment …

The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed
the effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide …

Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …

SARS-CoV-2 Omicron (B.1.1.529) BA.4 and BA.5 sub-lineages, first detected in South Africa,
have changes relative to Omicron BA.1 including substitutions in the spike receptor binding …

Background We previously reported that integrating antiretroviral therapy (ART) with
tuberculosis treatment reduces mortality. However, the timing for the initiation of ART during …

As of May 31, 2022, there were 6· 9 million reported deaths and 17· 2 million estimated
deaths from COVID-19, as reported by the Institute for Health Metrics and Evaluation (IHME; …

An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals
is needed to guide vaccine design and immunization strategies. Here we used a large …